Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.56 |
| ▸ | VCP | P55072 | 5/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683416 | 0.93 | KDR (0.53) | KDRMCHR1VCPHRH3KDM4E | |
| SCHEMBL13683417 | 0.90 | KDR (0.56) | KDRMCHR1VCPHRH3KDM4E | |
| Hydrochloric Acid SCHEMBL3866759 | 0.89 | KDR (0.56) | KDRMCHR1VCPHRH3KDM4E | |
| SCHEMBL3863589 | 0.84 | KDR (0.51) | KDRMCHR1HRH3KDM4E | |
| SCHEMBL13660199 | 0.83 | MCHR1 (0.79) | KDRMCHR1KDM4E | |
| SCHEMBL13683431 | 0.83 | KDR (0.52) | KDRMCHR1HRH3KDM4E | |
| SCHEMBL4005248 | 0.83 | KDR (0.58) | KDRMCHR1HRH3KDM4E | |
| Hydrochloric Acid SCHEMBL3859106 | 0.83 | KDR (0.51) | KDRMCHR1VCPHRH3KDM4E | |
| SCHEMBL4263943 | 0.83 | MCHR1 (0.63) | KDRMCHR1KDM4E | |
| SCHEMBL13683432 | 0.82 | KDR (0.53) | KDRMCHR1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-20050245500-A1 | Beta-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245500-A1 | Beta-ketoamide compounds with MCH antagonistic activity | MCHR2, MCHR1, NPY1R | KDR 3003/4885MCHR1 2/4885VCP 4375/4885 |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | KDR 4837/4885MCHR1 1/4885VCP 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.